• BIOTECH INVESTMENT
• VENTURE CAPITAL
• PRICE OF NEW DRUGS
• REIMBURSEMENT
HOW NEW DEVELOPMENT MODELS CAN LEAD TO CANCER BREAKTHROUGHS by Dan Dupuis
The pharmaceutical industry’s long and successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters, worked well for many years, but its R&D productivity has now plummeted and the environment is changing. Read More…
CAN A NEW DEVELOPMENT MODEL PREVENT COSTLY PHASE III DRUG DEVELOPMENT FAILURES? by Dan Dupuis
Attaining FDA approval for a new drug is certainly the ultimate goal of any drug research initiative. Accelerating that process can not only prove to be beneficial to patients, but is also a key component of increasing the return on investment for any entity that has a vested interest in a new medication. Read More…
4 DRUG AND BIOTECH STOCKS AWAITING FDA APPROVAL IN JULY 2018 by Kinjel Shah
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year. Read More…
HOW CAN OBESITY BOTH FUEL TUMOR GROWTH AND HELP NEW IMMUNOTHERAPY DRUGS WORK BETTER?
Two new studies have provided compelling insights into the relationship between obesity and cancer. The research reveals fascinatingly paradoxical effects, suggesting obesity can suppress our immune responses to enhance tumor growth, but also improve the efficacy of a new kind of cancer-killing immunotherapy. READ MORE…
Argentum Pharmaceuticals wins patent invalidation trial against the sole remaining patent protecting Janssen’s Zytiga.
The U.S. Patent & Trademark Office (PTO) issued a final written decision Wednesday in Argentum Pharmaceuticals LLC’s inter partes review (IPR) against the sole unexpired patent covering Janssen Oncology, Inc.’s Zytiga (abiraterone acetate). Janssen Oncology is a subsidiary of Johnson & Johnson. READ MORE…
ARE BOTANICAL DRUGS THE “NEXT BIG THING” IN PHARMACEUTICALS?
Almost all new drug development is on a quest to deliver maximum efficacy, while being not only safe, but well tolerated due to exhibiting few side effects. Anyone that has brought a prescription home from the pharmacy or listened to the warnings listed at the conclusion of any drug advertisement on television realizes that all conventional drugs have a long list of warnings about the dangers and side effects that are inherent to all medications. READ MORE…